Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 1
Submit an article Journal homepage
108
Views
17
CrossRef citations to date
0
Altmetric
Research Report

The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium

Jessica Fraeyman Epidemiology & Social Medicine, Research group Medical Sociology & Public Health, University of Antwerp, Antwerp, Belgium; Epidemiology & Social Medicine, Research group Medical Sociology & Public Health, University of Antwerp, Antwerp, Belgium. [email protected]
,
Guido Van Hal Epidemiology & Social Medicine, Research group Medical Sociology & Public Health, University of Antwerp, Antwerp, Belgium
,
Brian Godman Institute for Pharmacological Research ‘Mario Negri’, Via Giuseppe La Masa 19, 20156 Milan, Italy; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE‑141 86, Stockholm, Sweden; Institute for Pharmacological Research ‘Mario Negri’, Via Giuseppe La Masa 19, 20156 Milan, Italy; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE‑141 86, Stockholm, Sweden
&
Philippe Beutels Centre for Health Economics Research & Modeling Infectious Diseases, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
Pages 141-151 | Published online: 09 Jan 2014

References

  • Fraeyman J, Van Hal G, De Loof H, Remmen R, De Meyer GR, Beutels P. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium. Acta Clin. Belg. 67(3), 160–171 (2012).
  • Dylst P, Vulto A, Simoens S. Where a cheap medicine is not the same as a generic medicine: the Belgian case. J. Pharmaceut. Health Serv. Res. 2, 185–189 (2011).
  • Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10(6), 707–722 (2010).
  • Godman B, Shrank W, Wettermark B et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470–2494 (2010).
  • Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol. 1, 141 (2010).
  • Garattini S, Bertelé V, Godman B, Haycox A, Wettermark B, Gustafsson LL; Piperska Group. Enhancing the rational use of new medicines across European health care systems. Eur. J. Clin. Pharmacol. 64(12), 1137–1138 (2008).
  • Van Wilder P, Dupont A. Introducing evidence-based medicine in reimbursement procedures: does it affect the outcome? Value Health 11(4), 784–787 (2008).
  • Vrijens F, Van de Voorde C, Farfan-Portet MI, Vander Stichele R. Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data. Eur. J. Health Econ. 13(3), 315–325 (2012).
  • McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev. Pharmacoecon. Outcomes Res. 10(1), 73–85 (2010).
  • Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev. Pharmacoecon. Outcomes Res. 12(1), 125–130 (2012).
  • Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacoeconomics 27(5), 435–438 (2009).
  • Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9(1), 65–83 (2009).
  • Vermeylen M, Verpooten G, Beyers H. [Pharmaceutical Indicators. Pharmaceutical Dispensing in Ambulant Practice 2009]. National Institute for Health and Disability Insurance, Brussels, Belgium, 82 (2011).
  • Dylst P, Vulto A, Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev. Pharmacoecon. Outcomes Res. 11(6), 729–737 (2011).
  • Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoecon. Outcomes Res. 11(1), 121–129 (2011).
  • Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26(2), 91–98 (2008).
  • Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 9(5), 475–484 (2009).
  • Godman B, Malmstrom RE, Bennie M et al. Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency? Rev. Health Care. 3, 5–16 (2012).
  • Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J. Clin. Pharm. Ther. 35(2), 139–151 (2010).
  • Godman B, Paterson K, Malmstrom RE, Selke G, Fagot JP, Mrak J. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev. Pharmacoecon. Outcomes Res. 12(4), 439–441 (2012).
  • Pedersen TR, Faergeman O, Kastelein JJ et al.; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294(19), 2437–2445 (2005).
  • Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int. J. Clin. Pract. 63(9), 1320–1326 (2009).
  • Vlahovic-Palcevski V, Gantumur M, Radosevic N, Palcevski G, Vander Stichele R. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm. World Sci. 32(2), 125–129 (2010).
  • Voncina L, Strizrep T, Godman B et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 469–479 (2011).
  • Godman B, Godman B, Sermet C et al. European payer initiatives to reduce prescribing costs through use of generics. GABI 1, 22–27 (2012).
  • Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7(3), 137–147 (2009).
  • Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev. Pharmacoecon. Outcomes Res. 11(3), 343–349 (2011).
  • Borgermans L, Dubois C, Rieppi S et al. Impact of academic detailing on primary care physicians. KCE reports 125c, Belgian Health Care Knowledge Centre, Belgium (2010).
  • Vermeylen M, Verpooten G, Beyers H. The Efficient Use of Hypolipidemic Drugs. Committee for the Evaluation of the medical practice concerning Pharmaceuticals (CEP) of the National Institute for Health and Disability Insurance, Brussels (2002).
  • Topol EJ. Intensive statin therapy – a sea change in cardiovascular prevention. N. Engl. J. Med. 350(15), 1562–1564 (2004).
  • Verpooten G, Beyers H. [Consensus meeting of May 15th 2003. The efficient use of acid blockers in gastro-oesophageal reflux and dyspepsia. National Institute for Health and Disability Insurance, Brussels]. In: Folia Pharmacotherapeutica. RIZIV‑INAMI, Brussels, Belgium, 25 (2004).
  • van Driel ML, Vander Stichele R, Elseviers M, De Sutter A, De Maeseneer J, Christiaens T. Effects of an evidence report and policies lifting reimbursement restrictions for acid suppressants: analysis of the Belgian national database. Pharmacoepidemiol. Drug Saf. 17(11), 1113–1122 (2008).
  • van Driel ML, Vander Stichele R, De Maeseneer J, De Sutter A, Christiaens T. Medical evidence and health policy: a marriage of convenience? The case of proton pump inhibitors. J. Eval. Clin. Pract. 13(4), 674–680 (2007).
  • Vander Stichele R, Petri H. Utilization patterns of subsidized and nonsubsidized reimbursable peptic ulcer medication in Belgium. Pharmacoepidemiol. Drug Safety 4(4), 213–224 (1995).
  • Austvoll-Dahlgren A, Aaserud M, Vist G. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst. Rev. 23(1), CD007017 (2009).
  • Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 317(7156), 465–468 (1998).
  • Barton S. Using clinical evidence. BMJ 322(7285), 503–504 (2001).
  • van Woerkom M, Piepenbrink H, Godman B. Ongoing measures to enhance the efficiency of prescribing of PPIs and statins in The Netherlands; influence and future implications. J. Comparative Effectiveness Res. 1(6), 527–538 (2012).
  • Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24), 2947–2953 (2006).
  • Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102(9), 2047–2056 (2011).
  • Howell MD, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 170(9), 784–790 (2010).
  • Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 167(9), 950–955 (2007).
  • Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch. Intern. Med. 170(9), 765–771 (2010).
  • Katz MH. Failing the acid test – benefits of proton pump inhibitors may not justify the risks for many users. Arch. Intern. Med. 170, 747–748 (2010).
  • Dylst P, Simoens S. Generic Medicine pricing policies in Europe: current status and impact. Pharmaceuticals 3, 471–481 (2010).
  • Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl. Health Econ. Health Policy 8(1), 7–24 (2010).
  • Abuelkhair M, Abdu S, Godman B, Fahmy S, Malmström RE, Gustafsson LL. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi. Expert Rev. Pharmacoecon. Outcomes Res. 12(1), 115–124 (2012).
  • Godman B, Wettermark B, Bennie M et al. Enhancing prescribing efficiency through increased utilisation of generics at low price. Hospital 13(3), 28–31 (2011).
  • Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 9(6), 569–581 (2009).
  • Vitry A, Martin A, Godman B et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GABI 1(2), 21–35 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.